Results 51 to 60 of about 6,744 (185)

Quantitative analysis of thrombopoietin receptors on human megakaryocytes [PDF]

FEBS Letters, 1998
Thrombopoietin (TPO), or c‐MPL ligand, is the primary regulator of megakaryocyte and platelet production. TPO receptors expressed on human megakaryocytes derived from peripheral blood (PB) and cord blood (CB) progenitors cultured in the presence of TPO have now been analyzed quantitatively.
Kuwaki, Tomoaki, Hagiwara, Tetsuya, Yuki, Chizuru, Kodama, Ikuko, Kato, Takashi, Miyazaki, Hiroshi   +5 more
openaire   +2 more sources

The association of thrombocytopenia with haematological malignancy

British Journal of Haematology, EarlyView.
This review article discusses the interplay of immune dysregulation, clonality, and immunosuppressive therapies in immune thrombocytopenia and how this links to the risk of misattribution versus the development of haematological malignancy. Unresolved questions and directions for future research are also discussed. Isolated thrombocytopenia is commonly
Abi Vijenthira, Henrik Frederiksen, Michelle Sholzberg   +2 more
wiley   +1 more source

Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach

BMC Bioinformatics, 2009
Background The Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway is one of the most important targets for myeloproliferative disorder (MPD).
Lee Eunjung, Park Inho, Won Hong-Hee, Kim Jong-Won, Lee Doheon   +4 more
doaj   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia [PDF]

Seminars in Hematology, 2013
Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes.
Deborah, Siegal, Mark, Crowther, Adam, Cuker   +2 more
openaire   +2 more sources

Idiopathic thrombocytopenic purpura: laboratory diagnosis and management

Universa Medicina, 2016
Idiopathic thrombocytopenic purpura (ITP) or immune thrombocytopenic purpura is a disease characterized by low platelet count (
Alvina Alvina
doaj   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Eltrombopag for the treatment of aplastic anemia: current perspectives

Drug Design, Development and Therapy, 2016
Su Han Lum, John D GraingerDepartment of Blood and Marrow Transplant, Royal Manchester Children’s Hospital, Manchester, UK Abstract: Aplastic anemia (AA) is a potential life-threatening hematopoietic stem cell (HSC) disorder resulting in cytopenia.
Lum SH, Grainger JD
doaj  

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia

Hepatic Medicine: Evidence and Research, 2013
Fazal-i-Akbar Danish,1 Saeeda Yasmin21James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom; 2Shifa International Hospital, Islamabad, PakistanAbstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the
Danish FA, Yasmin S
doaj